The dose-response of diethylnitrosamine (DENA) initiation of hepatocarcinogenesis was determined in infant Balb/c male mice with and without subsequent phenobarbital treatment. Male Balb/c mice received a single intraperitoneal injection of DENA (0, 2.5, 10.0, 25.0 or 50.0 pglgbw) in saline on day 15 of age. Ninety mice were treated at each dose level. At weaning, mice received either deionized drinking water (45 mice per group) or deionized drinking water containing 500 mg/L sodium phenobarbital (PB) (45 mice per group). Mice from each group were sacrificed 12, 24, and 40 weeks post-weaning. Liver and lung tumors were found in DENA-only-treated and DENA + PB-treated mice. In DENA-only-treated mice, the incidence and number of hepatic adenomas were similar (not dose-dependent) at DENA doses of 10,25, and 50 pg/ gbw at each of the 3 sampling times. DENA-only-treated mice did display a time-related increase in hepatic adenoma incidence and number at each dose. In PB-treated mice, the hepatic adenoma number was dependent upon the dose of DENA between 2.5 and 50 pglgbw. PB treatment following DENA administration resulted in a decrease in the time required for the detection of hepatic adenomas and increased the number of hepatic adenomas at most sampling times compared to the mice that received DENA only. Hepatocellular carcinomas (HPC) were detected in mice receiving the highest DENA doses (25 and 50 pg/gbw). PB treatment increased the number and incidence of HPC and decreased the time of first detection of HPC. The incidence and number of lung adenomas per mouse induced in DENA-treated mice was linearly proportional to the DENA dose. PB had no influence on the incidence or number of DENA-induced lung adenomas.
INTRODUCTION
A critical question in the extrapolation ofcarcinogenicity results from rodent bioassays to the estimation of human health hazard is'the determination of carcinogenic potency of the low dose levels expected in potential human exposure. These low dose levels are usually below the level ofsensitivity of bioassays that contain less than 100 animals. For human risk assessment, the carcinogenic potency is usually required for a population of 100,000. Thus, as part of the risk assessment process, an estimate of the activity of low dose levels is obtained by extrapolation of the dose-response relationship. In this study, we determined the doseresponse rela-tionship of diethylnitrosamine in 15-day-old male Balb/c mice.
A number of rodent hepatocarcinogens appear to produce their tumorigenic effects through a nOngenotoxic/tumor Promotion mode of action (19) . Phenobarbital is one example of a non-genotoxic liver carcinogen. Chronic exposure of rats to phenobarbital has been shown to promote the n U~b e r and incidence of chemically induced hepatic aden-OmaS and carcinomas (8, 10, 15) . Similar studies in mice have produced differing results, however. Phenobarbital administered to B6C3Fl male mice initiated as adults with diethylnitrosamine (DENA) PromotedhePatiC tumor formation (1 1,17) . B6C3F1 mice, in contrast, treated with DENA on day 15 of age, and given long-term exposure to phenobarbital starting at weaning, resulted in an inhibition in the hepatic foci, adenomas, and carcinomas (1 , 5; 1 1).
Similarly, phenobarbital inhibited liver tumor development in A/HE mice that were previously treat-TOXICOLOGIC PATHOLOGY ed as infants with ethylnitrosourea (7) . In contrast, when DDD mice exposed to dimethylnitrosamine at birth were subsequently treated with phenobarbital, promotion of the liver tumors occurred (16) . Therefore, the opposing response to subsequent phenobarbital treatment has varied between inhibition and promotion of liver tumor formation in carcinogen-initiated infant mice.
The present study was undertaken to determine for DENA administered on day 15 of age the dose and temporal relationship of the induction of liver and lung tumors in Balb/c male mice and to investigate the effect of phenobarbital treatment, following DENA initiation of these mice, on this doseresponse relationship. The Balb/c strain of mouse was chosen for these studies because it has been used extensively in carcinogenicity studies, and in contrast to other strains of mice its spontaneous incidence of liver and lung tumors is very low, while it is sensitive to the induction of pulmonary and hepatic tumors by chemical carcinogens (6).
MATERIALS AND METHODS

Chemicals
Diethylnitrosamine (DENA) was purchased from Eastman Kodak Company (Rochester, NY) and sodium phenobarbital from J. Baker Company (Phillipsburg, NJ).
Animals
Adult male and female Balb/c mice were purchased from Charles River Breeding Laboratories . 
Experimeiital Design
Infant male Balb/c mice received a single intraperitoneal injection of one of 4 concentrations (2.5, 10.0,25.0, or 50 pg/gbw) of DENA in saline at day 15 of age. Ninety mice were treated at each dose. An additional 90 mice received only saline. At weaning (28 days of age), one half of the mice for each dosage group (45 mice) received sodium phenobarbital (500 mg/L deionized water) in their drinking water until they were sacrificed. The remaining mice received deionized water. Drinking water was changed daily. Mice were sacrificed at 12 weeks (1 0 mice), 24 weeks (1 5 mice), and 40 weeks (20 mice) post-weaning. At sampling, mice were humanely killed by fatal anesthesia, weighed and necropsied.
The livers and lungs were removed in toto, weighed, and examined for the presence of grossly visible lesions. The number and location of these lesions were recorded. In addition, the remaining liver was sliced at 2-mm intervals and fixed in 10% phosphate buffered formalin. Lungs were fixed iii toto in buffered formalin. Formalin fixed livers and lungs were dehydrated, embedded in paraffin, and sectioned. Paraffin sections were stained with hematoxylin and eosin. Hepatic lesions were quantitated and histologically classified into 3 morphologic types; focal areas of cellular alteration (foci), hepatocellular adenomas, and hepatocellular carcinomas using criteria previously used by us and defined (2, 5, 6, 18) . Lung lesions were also quantitated and histologically classified for each mouse (14) . The results were statistically analyzed using the Fisher's exact test and analysis of variance (AN-OVA) and tested for significance by the Tukey post hoc test (3). No quantitation of foci was performed.
RESULTS
The body weight and liver weight/body weight ratios for the treated and control mice at 12, '24, and 40 weeks post-weaning were determined (data not shown). No statistical difference was found between the body weights of mice from the 9 treatment groups and the untreated control group at each sampling time. However, mice treated with PB displayed significantly ( p c 0.05) increased liver weight/ body weight ratios compared to non-PB-treated mice at all sampling times. In addition, mice treated with DENA only at all dose levels exhibited a significant increase (p < 0.05) in liver weightjbody weight ratios over that of the untreated control mice at the 40-week sampling time.
Hepatic adenoma incidence and adenoma number per mouse in DENA-only, PB-only, DENA + PB and untreated Balb/c male mice after 12,24, and 40 weeks post-weaning are shown in Table I . Untreated mice and mice treated only with PB exhibited no hepatic adenomas at any of the sampling times. The administration of PB after DENA treatment resulted in a more rapid onset of adenomas appearance and a greater incidence of hepatic adenomas compared to the corresponding mice administered DENA only. Hepatic adenomas did not occur in DENA-only-treated mice at dosages of 2.5, 10, and 25 pg/gbw) until 24 weeks (20 weeks when a linear extrapolation is applied to the data). When DENA treatment was followed by PB treatment, <Adenoma incidence reflects the number of mice with tumordtotal number of mice at risk.
-Denotes that the value was significantly increased (p < 0.05) from non-DENA-treated mice of the same age. 'Denotes that the value was significantly increased (p < 0.05) in mice treated with phenobarbital over that of mice of the same sampling time and same DENA treatment that had not received phenobarbital.
hepatic adenomas occurred by 12 weeks post-weaning (9 weeks by linear extrapolation) in all treatment groups. Thus, PB decreased the time to hepatic adenoma formation for DENA-initiated mice. For DENA concentrations between 10 and 50 pg/ gbw, a DENA dose-related increase in tumor incidence was observed only in the groups that received subsequent treatment with PB. Treatment with PB significantly increased the number of hepatic adenomas induced by 2.5,10,25, and 50 pg/gbwDENA at each sampling time over that of non-PB-treated mice.
Trabecular hepatocellular carcinomas were de-tected in mice treated with 25 and 50 pg/gbw DENA at the 24-and 40-week sampling times (Table 11) . Treatment with PB decreased the time to carcinoma appearance and increased the incidence of carcinomas compared to mice treated with DENA only. The lung tumor incidence and the number of lung tumors per animal in Balb/c mice treated with DENA only or with DENA + PB is shown in Table 111 . All pulmonary tumors were classified histologically as adenomas. Lung tumors were detected in untreated and PB-only-treated mice at the 40-week sampling period. DENA induced a dose-dependent increase in the number of lung adenomas per mouse at each (14) similarly found that carcinogen-induced lung tumors in the Strain A mouse were linearly related to the dose of carcinogen. Liver adenoma incidence and number (at DENA concentrations of 10,25, and 50 pg/gbw) in the absence of PB treatment was not related to the dose of DENA. This lack of a dose-related increase in the incidence of DENA-induced liver adenomas suggests either the saturation of the number of potential initiated sites in the liver, and/or rate limiting step(s) in the progression of DENA-initiated cells to tumors. When DENA initiation was followed by PB treatment, the number of hepatic adenomas was related to the dose of DENA (at all DENA doses studied). This would suggest that the number of DENA-initiated sites were not saturated but rather that the progression of the initiated cell to tumors was limiting in the absence of PB treatment. Whichever the mechanism, our results indicate that the extrapolation from the tumor response from high dose levels of DENA to predict the tumor response of a lower dose could, thus, result in an under-estimation of carcinogenic activity.
PB is not genotoxic and in the present study failed to induce hepatic tumors in the Balb/c mouse (4). Two proposed mechanisms for the enhancement by PB of the number of DENA-initiated liver adenomas are comparable with our results, i.e., increasing the progression of initiated cells to adenomas and/ or decreasing the regression of initiated cells. The fact that PB treatment 1) resulted in a dose-related increase of DENA-initiated tumors between 10 and 50 pg/gbw DENA while in the absence of PB, the response to DENA (10-50 pg/gbw) was saturated and 2) increased the incidence of DENA-initiated tumors while decreasing the time to tumor occurrence would suggest that PB overcomes the rate limiting step@) between the DENA initiation and the occurrence of tumors. It has been previously reported in rat liver that PB increases the incidence of DENA-initiated gamma-glutamyl transpeptidase-foci which are putative preneoplastic lesions, probably both by enhancing their growth and by preventing their regression (9) . PB has been shown to prevent phenotypic regression of hepatic foci and increase foci growth in the rat (12, 13). Thus, PB may also be functioning to enhance the incidence of DENA-initiated liver tumors in mice both by preventing the regression of DENA-initiated cells and by stimulating the progression of DENA-initiated cells to tumors. The lack of an effect of PB on chemically initiated lung adenomas is consistent with previous observations (7, 9, 15) . In Swiss (CD-1) mice initiated with ethylnitrosourea on day 15 of age, long-term exposure to PB begun at 4 weeks of age enhanced the formation of liver tumors (9) . Similarly, in DDD mice initiated on day 1 of age with dimethylnitrosamine, long-term exposure to phenobarbital also resulted in an enhancement of tumor occurrence (1 6). In contrast, in B6C3F1 mice (1,5, 1 1) and in A/He mice (7) beginning long-term exposure to phenobarbital at 4 weeks of age suppressed the occurrence of liver tumors in mice initiated on day 15 of age with DENA or on day 1 of age with ENU, respectively. Thus, phenobarbital enhanced chemically initiated hepatocarcinogenesis in infant Balb/c, DDD and Swiss mice but inhibited hepatocarcinogenesis in infant B6C3F1 and A/He mice. The use of differing experimental protocols, especially different carcinogens, however, precludes the attributing of the opposing effect of PB to strain variation and/or to the age of the mice at initiation and/or the start of PB treatment.
